Targeting Ubiquitin-Proteasome system (UPS) in treating osteoarthritis

Area of Science:

• Biochemistry
• Molecular Biology
• Rheumatology

Background:

• Osteoarthritis (OA) is a prevalent, debilitating joint disease with incompletely understood pathophysiology.
• Ubiquitination (Ub) and related modifications are emerging as key players in OA development.
• Chondrocytes are central to OA pathogenesis, making them a focus for therapeutic targeting.

Purpose of the Study:

• To review recent advances in Ub and deubiquitinating enzyme (DUB) research relevant to OA.
• To explore the potential of targeting Ub-related pathways for OA therapeutic strategies.
• To highlight the role of Ub/DUBs in cartilage degradation and inflammation in OA.

Main Methods:

• Literature review of studies on Ub ligases and DUBs in OA.
• Analysis of Ub/DUB involvement in extracellular matrix (ECM) degradation.
• Examination of Ub-mediated regulation of inflammatory pathways, including NF-κB.

Main Results:

• Ub and DUBs significantly influence OA pathogenesis by regulating proteases like MMPs and ADAMTS.
• Ubiquitin-conjugating enzymes (E2) and ubiquitin-ligating enzymes (E3) are implicated in ECM degradation in OA.
• Ub-dependent mechanisms regulate inflammatory signaling pathways, such as NF-κB, contributing to OA.

Conclusions:

• Targeting the ubiquitin-proteasome system (UPS) presents a promising therapeutic avenue for OA.
• Further research into Ub/DUBs in chondrocytes and inflammatory pathways is crucial for developing effective OA treatments.
• Insights from clinical trials will guide future investigations into UPS-targeted OA therapies.